{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:57:06Z","timestamp":1790690226785,"version":"4.1.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,23]],"date-time":"2021-10-23T00:00:00Z","timestamp":1634947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.semcancer.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T13:04:25Z","timestamp":1635167065000},"page":"170-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Precision diagnostics in lymphomas \u2013 Recent developments and future directions"],"prefix":"10.1016","volume":"84","author":[{"given":"Larry","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birna","family":"Thorvaldsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4636-1579","authenticated-orcid":false,"given":"Stamatia","family":"Laidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0211-8788","authenticated-orcid":false,"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2021.10.007_bib0005","unstructured":"S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele (Eds.), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Rev. 4th E, 2017."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0010","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S1470-2045(15)00620-8","article-title":"Precision oncology: origins, optimism, and potential","volume":"17","author":"Prasad","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/hon.2847","article-title":"Molecular classification of aggressive lymphomas\u2014past, present, future","volume":"39","author":"Wienand","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0020","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0025","article-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008","journal-title":"IARC Lyon."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0030","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/joim.12633","article-title":"Genetic landscape and deregulated pathways in B-cell lymphoid malignancies","volume":"282","author":"Rosenquist","year":"2017","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0035","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3324\/haematol.2015.134510","article-title":"Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond","volume":"101","author":"Rosenquist","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0040","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0045","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0050","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3324\/haematol.2013.096248","article-title":"B-cell lymphoma mutations: Improving diagnostics and enabling targeted therapies","volume":"99","author":"Vaqu\u00e9","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0055","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1056\/NEJMc1111708","article-title":"TET2 and DNMT3A mutations in human T-Cell lymphoma","volume":"366","author":"Couronn\u00e9","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0060","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1056\/NEJMoa1114885","article-title":"Somatic STAT3 mutations in large granular lymphocytic leukemia","volume":"366","author":"Koskela","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0065","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1182\/blood-2013-10-531509","article-title":"A targeted mutational landscape of angioimmunoblastic T-cell lymphoma","volume":"123","author":"Odejide","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0070","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2872","article-title":"Somatic RHOA mutation in angioimmunoblastic T cell lymphoma","volume":"46","author":"Sakata-Yanagimoto","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0075","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1182\/blood-2012-06-435297","article-title":"STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia","volume":"120","author":"Jerez","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0080","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1158\/1078-0432.CCR-14-2759","article-title":"Genetics and prognostication in splenic marginal zone lymphoma: revelations from deep sequencing","volume":"21","author":"Parry","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0085","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/leu.2014.330","article-title":"KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype","volume":"29","author":"Clipson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0090","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0095","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/ng.3473","article-title":"Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma","volume":"48","author":"Okosun","year":"2016","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0100","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0110","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1182\/blood-2016-03-704528","article-title":"Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma","volume":"128","author":"Mansouri","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0115","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1182\/blood-2012-02-408542","article-title":"Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters","volume":"120","author":"Lemonnier","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0120","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0125","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.3324\/haematol.2015.133074","article-title":"A highly recurrent novel missense mutation in CD28 among angioimmunoblastic T-cell lymphoma patients","volume":"100","author":"Lee","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0130","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/nature07968","article-title":"Mutations of multiple genes cause deregulation of NF-\u03baB in diffuse large B-cell lymphoma","volume":"459","author":"Compagno","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0135","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0140","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1182\/blood-2013-12-546309","article-title":"Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients","volume":"124","author":"de Miranda","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34\u2013expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0150","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"D\u00f6hner","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0155","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2010.039768","article-title":"Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia","volume":"96","author":"Gunnarsson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0160","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","article-title":"TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics","volume":"103","author":"Campo","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0165","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","article-title":"The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype","volume":"23","author":"Dicker","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0170","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1182\/blood-2009-07-234708","article-title":"Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage","volume":"114","author":"Malcikova","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0175","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","article-title":"Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial","volume":"114","author":"Zenz","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0180","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41375-017-0007-7","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia\u2014update on methodological approaches and results interpretation","volume":"32","author":"Malcikova","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0185","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0190","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0195","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2011.049270","article-title":"ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression","volume":"97","author":"Guarini","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0200","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1365-2141.2010.08368.x","article-title":"NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL","volume":"151","author":"Sportoletti","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0210","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2011-09-379966","article-title":"Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0215","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3324\/haematol.2011.060129","article-title":"NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL","volume":"97","author":"Del Giudice","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0220","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0225","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1038\/leu.2013.218","article-title":"Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients","volume":"27","author":"Weissmann","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0230","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/leu.2012.307","article-title":"NOTCH1 and SF3B1 mutations can be added to the hierarchical prognostic classification in chronic lymphocytic leukemia","volume":"27","author":"Mansouri","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0235","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0240","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","article-title":"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial","volume":"121","author":"Oscier","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0245","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","article-title":"SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients","volume":"28","author":"Jeromin","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0250","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2013-03-488197","article-title":"NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG","volume":"122","author":"Schnaiter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0255","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/leu.2013.333","article-title":"On the way towards a \u201cCLL prognostic index\u201d: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort","volume":"28","author":"Cortese","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0260","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0265","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.20142009","article-title":"Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia","volume":"212","author":"Mansouri","year":"2015","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0270","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","article-title":"Acquired initiating mutations in early hematopoietic cells of CLL patients","volume":"4","author":"Damm","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0275","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/leu.2016.359","article-title":"EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia","volume":"31","author":"Young","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0280","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2015-10-674572","article-title":"Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations","volume":"127","author":"Ljungstrom","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0285","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0290","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/leu.2013.319","article-title":"Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia","volume":"28","author":"Arruga","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0295","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20131448","article-title":"Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome","volume":"210","author":"Fabbri","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0300","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0305","article-title":"Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1","volume":"105","author":"Tausch","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0310","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2014.109777","article-title":"Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting","volume":"100","author":"Sutton","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2016.10.005","article-title":"Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia","volume":"30","author":"Wang","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0320","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2013-02-486209","article-title":"Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0325","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/leu.2013.98","article-title":"Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2","volume":"27","author":"Strefford","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0330","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3324\/haematol.2016.141812","article-title":"Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors","volume":"101","author":"Sutton","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0335","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1182\/blood.2020005216","article-title":"Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169","volume":"137","author":"Gemenetzi","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0340","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3324\/haematol.2019.219550","article-title":"Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia","volume":"105","author":"Diop","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0345","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1158\/1078-0432.CCR-18-4158","article-title":"The number of signaling pathways altered by driver mutations in chronic lymphocytic leukemia impacts disease outcome","volume":"26","author":"Brieghel","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0350","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-020-00389-w","article-title":"Genetic and epigenetic determinants of diffuse large B-cell lymphoma","volume":"10","author":"Bakhshi","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0355","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0360","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-Cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0365","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0370","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2007-02-072082","article-title":"Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma","volume":"110","author":"Young","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0375","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1182\/blood-2008-01-129783","article-title":"Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study","volume":"112","author":"Young","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0380","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an international DLBCL Rituximab-CHOP consortium program study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0385","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2009-10-247122","article-title":"Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study","volume":"116","author":"Jardin","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0390","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-017-0438-7","article-title":"Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38\/07 prospective clinical trial cohort","volume":"10","author":"Juskevicius","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0395","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1182\/bloodadvances.2020001696","article-title":"Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma","volume":"4","author":"Rushton","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0400","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0405","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0410","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/PAS.0b013e31826cebad","article-title":"Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas","volume":"37","author":"Pillai","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0415","doi-asserted-by":"crossref","first-page":"e2388","DOI":"10.1097\/MD.0000000000002388","article-title":"Impact of single or combined genomic alterations of TP53, MYC, and BCL2 on survival of patients with diffuse large B-Cell lymphomas: a retrospective cohort study","volume":"94","author":"Schiefer","year":"2015","journal-title":"Med"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0420","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.18632\/oncotarget.6262","article-title":"Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma","volume":"7","author":"Ye","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0425","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1182\/blood.2019002067","article-title":"Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade","volume":"134","author":"Chapuy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0430","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1080\/10428194.2018.1542144","article-title":"ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients","volume":"60","author":"Mareckova","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0435","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0440","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","article-title":"KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study","volume":"105","author":"Ferrero","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0445","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/cancers12082120","article-title":"Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy","volume":"12","author":"Malarikova","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0450","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"European Mantle Cell Lymphoma Network, High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0455","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1182\/blood-2011-11-391474","article-title":"Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma","volume":"119","author":"Kridel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0460","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0465","doi-asserted-by":"crossref","first-page":"73558","DOI":"10.18632\/oncotarget.12434","article-title":"CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma","volume":"7","author":"Mohanty","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0470","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0475","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","article-title":"Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes","volume":"136","author":"Nadeu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0480","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood.2019002385","article-title":"Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing","volume":"136","author":"Pararajalingam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0485","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41375-020-0934-6","article-title":"Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma","volume":"35","author":"Lantermans","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0490","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kruppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma","volume":"29","author":"Piva","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-46906-1","article-title":"Systematic review of somatic mutations in splenic marginal zone lymphoma","volume":"9","author":"Jaramillo Oquendo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0500","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1182\/blood-2016-02-696757","article-title":"The genetics of nodal marginal zone lymphoma","volume":"128","author":"Spina","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0505","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.3324\/haematol.2016.161711","article-title":"Clinical and diagnostic relevance of NOTCH2-and KLF2-mutations in splenic marginal zone lymphoma","volume":"102","author":"Campos-Martin","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0510","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom\u2019s macroglobulinemia","volume":"98","author":"Nguyen-Khac","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0515","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 mutation and its prognostic significance in Waldenstrom\u2019s macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0520","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m\u2019s Macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0525","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of somatic mutations in patients with Waldenstr\u00f6m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0530","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-019-0132-x","article-title":"Follicular lymphoma","volume":"5","author":"Carbone","year":"2019","journal-title":"Nat Rev Dis Prim."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0535","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0540","doi-asserted-by":"crossref","DOI":"10.1038\/s41568-020-0247-0","article-title":"Peripheral T cell lymphomas: from the bench to the clinic","volume":"20","author":"Fiore","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0545","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1038\/s41375-019-0473-1","article-title":"Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling","volume":"2019","author":"Watatani","year":"2019","journal-title":"Leuk"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0550","doi-asserted-by":"crossref","DOI":"10.1038\/ng.3358","article-title":"Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma","volume":"47","author":"Jiang","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0555","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-04-497933","article-title":"PRDM1\/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma","volume":"122","author":"Boi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0560","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0565","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0570","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0575","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0580","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1056\/NEJMoa1215637","article-title":"Ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0585","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0590","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.3324\/haematol.2018.205229","article-title":"Ibrutinib for the treatment of relapsed\/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis","volume":"104","author":"Rule","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0595","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1074\/jbc.M113.457440","article-title":"RIF1 counteracts BRCA1-mediated end resection during DNA repair","volume":"288","author":"Feng","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0600","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0605","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0610","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study","volume":"166","author":"Nordstr\u00f6m","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0615","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0620","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0625","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/leu.2017.110","article-title":"PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment","volume":"31","author":"Jones","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0630","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0635","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0640","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1038\/s41375-018-0335-2","article-title":"Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment","volume":"33","author":"Gounari","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0645","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0650","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.2770.2770","article-title":"Whole-exome sequencing revealed no recurrent mutations within the PI3K pathway in relapsed chronic lymphocytic leukemia patients progressing under idelalisib treatment","volume":"128","author":"Ghia","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0655","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0660","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstrom macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0665","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0670","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-130396","article-title":"Survival outcomes in patients with Waldenstr\u00f6m macroglobulinemia\/ lymphoplasmacytic lymphoma according to MYD88 mutation status","volume":"134","author":"Mian","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0675","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0680","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0685","doi-asserted-by":"crossref","first-page":"38180","DOI":"10.18632\/oncotarget.9500","article-title":"Genetic heterogeneity in primary and relapsed mantle cell lymphomas: impact of recurrent CARD11 mutations","volume":"7","author":"Wu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0690","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2017-03-734533","article-title":"The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice","volume":"130","author":"Kuo","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0695","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Rossi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0700","series-title":"Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia","author":"Nadeu","year":"2018"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0705","article-title":"Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study","author":"Sutton","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0710","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jmoldx.2017.11.010","article-title":"Assessment of capture and amplicon-based approaches for the development of a targeted next-generation sequencing pipeline to personalize lymphoma management","volume":"20","author":"Hung","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0715","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0720","article-title":"LYNX (LYmphoid NeXt-generation sequencing) panel: a comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies","author":"Navrkalova","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0725","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.3324\/haematol.2016.155424","article-title":"Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing","volume":"102","author":"Wren","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0730","first-page":"3188","article-title":"Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders","volume":"5","author":"Stewart","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0735","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0740","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0745","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non\u2013germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0750","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1080\/10428194.2021.1907371","article-title":"Phase 1b\/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed\/refractory diffuse large B-cell lymphoma*","volume":"62","author":"Wilson","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0755","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0760","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0765","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0770","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0775","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0780","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01011-z","article-title":"New agents and regimens for diffuse large B cell lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0785","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0790","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0795","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase ii pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0800","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1182\/blood.2020009617","article-title":"Acalabrutinib in treatment-naive chronic lymphocytic leukemia","volume":"137","author":"Byrd","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0805","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO.20.01501","article-title":"Diffuse large B-Cell lymphoma\u2019s new genomic the bridge and the chasm","volume":"38","author":"Crombie","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0810","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11899-019-0493-y","article-title":"The emerging role of liquid biopsies in lymphoproliferative disorders","volume":"14","author":"Crombie","year":"2019","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0815","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2017-03-735639","article-title":"High-throughput sequencing for noninvasive disease detection in hematologic malignancies","volume":"130","author":"Scherer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0820","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0825","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1073\/pnas.1701263114","article-title":"Functional proteogenomics reveals biomarkers and therapeutic targets in lymphomas","volume":"114","author":"Rolland","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0830","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-37273-4","article-title":"Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma","volume":"9","author":"Fornecker","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0835","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25403-y","article-title":"Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia","volume":"12","author":"Bloehdorn","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2021.10.007_bib0840","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2008.281","article-title":"Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge","volume":"23","author":"Boerma","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0845","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1182\/blood.2019001880","article-title":"The whole-genome landscape of Burkitt lymphoma subtypes","volume":"134","author":"Panea","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0850","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1182\/blood-2013-07-517177","article-title":"The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells","volume":"123","author":"Zhang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0855","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","article-title":"The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma","volume":"121","author":"Meissner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0860","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/leu.2017.251","article-title":"Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets","volume":"32","author":"Karube","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0865","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2013-01-479865","article-title":"Analysis of FOXO1 mutations in diffuse large B-cell lymphoma","volume":"121","author":"Trinh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.10.007_bib0870","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21002650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21002650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:59:13Z","timestamp":1760918353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X21002650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":174,"alternative-id":["S1044579X21002650"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.10.007","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision diagnostics in lymphomas \u2013 Recent developments and future directions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}